Compare PDYN & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDYN | ALLO |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.5M | 252.9M |
| IPO Year | N/A | 2018 |
| Metric | PDYN | ALLO |
|---|---|---|
| Price | $7.45 | $2.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $8.00 | ★ $8.27 |
| AVG Volume (30 Days) | 2.0M | ★ 4.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $250.22 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.14 | $0.86 |
| 52 Week High | $12.79 | $2.80 |
| Indicator | PDYN | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 56.27 | 65.34 |
| Support Level | $6.87 | $1.01 |
| Resistance Level | $7.89 | N/A |
| Average True Range (ATR) | 0.52 | 0.20 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 86.27 | 79.03 |
Palladyne AI Corp is a software company focused on autonomy for robotic systems and solutions. Its artificial intelligence and machine learning software seeks to revolutionize the capabilities of robots, enabling them to observe, learn, reason, and act in structured and unstructured environments. AI and ML software platform of the company empowers robots to perceive variations or changes in the real-world environment, enabling them to autonomously maneuver and manipulate objects accurately in response. Palladyne AI software has wide application, including in industries such as automotive, aviation, construction, defense, general manufacturing, infrastructure inspection, logistics and warehousing.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.